Firstly, my deepest condolences on your father. It is a devastating disease and cuts the life of too many too short. I too share a similar wish that cell therapy were available to all as a close family member of mine passed away recently with a heart condition. I feel a loss like that really makes one reflect on their own life, paths taken and decisions made with a view to do better in the future.
On your question about Paul and Leslie being on both boards and the possibility of IMU and CHM merging... anything is possible. But I personally don't think it would make sense where they are both now from a strategy and corporate set-up perspective. It may also be an independence / legal nightmare.. who's best interest are they working for?
Though I agree a CAR-T and and oncolytic virus could conceivably be used as a combination therapy to target solid cancers.. you can achieve that through a partnership or collaboration. Typically you need a lot more than compatible assets to merge two companies.
Also the strategies of the two companies are currently heading into very different directions and both companies are 110% focused on getting just ONE of their products to market. The only reason why they'd even consider a merger is if they needed each other to achieve that. But that is clearly not the case here. Each have their own path to market and they are very distinct in both target market and approach.
Staying separate companies also makes them each more attractive take-over targets, as the less complex and more focused your business is on a single strategy.. the easier you are to integrate into a large pharma.
But I think the ultimate answer lies in the fact that PH chose to list CHM as a new ASX listed company with a clearly different class of asset in the oncology space. If he wanted a merged company, Paul would have had IMU purchase the CLTX asset instead of CHM. I think the answer lies in that simple decision made by PH, and I feel it was largely because he wanted a blank canvas to target the CAR-T space with the opportunity to hire the right people to tackle this CAR-T market as opposed to burden IMU with more expensive employees who specialise in CAR-T.. as well as distract IMU's focus on getting their current product on market. Two very different companies, both with highly specialised teams who are experts in their own respective fields.. doesn't really make sense to me anyway.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)